论文部分内容阅读
目的探讨立体超选择动脉灌注区域靶向新辅助化疗对“三阴”乳腺癌的临床疗效以及预后影响。方法“三阴”乳腺癌患者47例,其中Ⅱ期32例,Ⅲ期10例,Ⅳ期5例。随机分为2组:靶向化疗组(24例),术前行立体超选择动脉灌注化疗,其中10例采用MEF方案,14例采用EP方案;对照组(23例):分别采用CMF,CEF,EP方案进行常规新辅助化疗。观察其疗程、病灶变化和预后情况。结果靶向化疗组平均疗程(14.3±2.4)d,病灶缓解率(CR+PR)为91.6%;对照组平均疗程(30.5±3.8)d,病灶缓解率(CR+PR)为85%。靶向化疗组平均疗程明显低于对照组(P<0.01)。47例患者中9例在2年内死亡,其中靶向化疗组2例(均为Ⅳ期患者),对照组7例(Ⅱ期2例,Ⅲ期4例,Ⅳ期1例)。结论立体超选择动脉灌注新辅助靶向化疗作为“三阴”乳腺癌的辅助治疗,具有效果好、疗程短、预后佳等优点,是一种有效的“三阴”乳腺癌靶向治疗方法。
Objective To investigate the clinical efficacy and prognosis of targeted neoadjuvant chemotherapy in the treatment of “Sanyin ” breast cancer in three-dimensional superselective arterial perfusion regions. Methods “Sanyin ” 47 cases of breast cancer patients, including 32 cases of stage Ⅱ, 10 cases of stage Ⅲ, 5 cases of stage Ⅳ. Twenty-four patients were randomly divided into two groups: target chemotherapy group (24 patients), preoperative three-dimensional superselective arterial infusion chemotherapy, of which 10 patients with MEF regimen and 14 patients with EP regimen; control group (23 patients): CMF, CEF , EP regimen routine neoadjuvant chemotherapy. Observe the course of treatment, lesions and prognosis. Results The average response rate of the targeted chemotherapy group was (14.3 ± 2.4) days and the response rate of CR was 91.6%. The average duration of treatment was (30.5 ± 3.8) days in the control group, and the CR + PR was 85%. The average duration of chemotherapy in the targeted chemotherapy group was significantly lower than that in the control group (P <0.01). Nine of the 47 patients died within 2 years, including 2 in the targeted chemotherapy group (all in stage IV) and 7 in the control group (2 in stage II, 4 in stage III, and 1 in stage IV). Conclusions Stereotactic neoadjuvant targeted chemotherapy is an effective adjuvant therapy for Sanyin breast cancer with good effect, short course of treatment and good prognosis. To the treatment.